Last reviewed · How we verify
H10407
At a glance
| Generic name | H10407 |
|---|---|
| Also known as | Experimental |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults (PHASE1, PHASE2)
- Challenge Study of an ETEC Vaccine (PHASE2)
- Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge Strains (PHASE1)
- Low-dose Challenge Model With Enterotoxigenic E Coli (PHASE1)
- Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea (PHASE2)
- Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H10407 CI brief — competitive landscape report
- H10407 updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI